BridgeBio Pharma, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Neil Kumar
- Full Time Employees
- 839
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 3160 Porter Drive Palo Alto CA United States 94304
- IPO Date
- Jun 27, 2019
- CIK
- 0001743881
- Website
- bridgebio.com
- Similar Companies
- Business
- BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing and delivering transformative medicines to patients with genetic diseases and cancers. The company’s core products and services include the research, development, and commercialization of novel drug candidates targeting genetic disorders and oncology indications. BridgeBio’s portfolio encompasses multiple clinical and preclinical programs across areas such as rare diseases, oncology, and precision medicine, featuring therapies in pipeline development as well as marketed products. BridgeBio operates primarily in the United States but also engages in global clinical trials and partnerships to expand its reach. Founded in 2015 and headquartered in Palo Alto, California, the company leverages its drug development expertise through subsidiaries and strategic alliances with academic institutions, pharmaceutical companies, and biotechnology firms. Recent major company developments include significant funding rounds to advance its pipeline programs; strategic partnerships to enhance its research capabilities; acquisitions aimed at broadening its therapeutic areas and bolstering its technology platforms; and the launch of new investigational drugs targeting underserved genetic conditions. These moves have reinforced BridgeBio’s commitment to advancing precision medicine and expanding its impact in the rare disease and oncology markets. The company continues to evolve its pipeline with a focus on rapid clinical development and commercialization of targeted therapies to improve patient outcomes.
Company News
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $715,000 in BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript